Carboplatin Hydrogen-Bond Complex for Lower Toxicity and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing platinum-based anticancer drugs like cisplatin and carboplatin face issues with stability in aqueous solutions, toxicity, and drug resistance, which hinder their clinical effectiveness and application.
Innovation Solution
A carboplatin complex is formed through hydrogen bonding with 1,1-cyclobutanedicarboxylic acid, enhancing water solubility, stability, and reducing toxicity by blocking platinum's DNA binding, thereby forming a stable complex with improved bioavailability and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If carboplatin is used as an anticancer drug, then antitumor efficacy is achieved, but toxicity and side effects occur
Solution Approach 1:
1,1-cyclobutanedicarboxylic acid serves as a mediator that forms a complex with carboplatin through hydrogen bonding. This complex acts as an intermediary that reduces the direct toxic interaction between carboplatin and healthy cells while preserving the antitumor efficacy against resistant cancer cells.
Solution Approach 2:
The invention changes the chemical parameters of carboplatin by forming a complex with 1,1-cyclobutanedicarboxylic acid. This parameter change modifies the drug's properties including reduced nephrotoxicity, ototoxicity, and neurotoxicity while maintaining its antitumor activity.
2Duration of action of moving object
If platinum-based drugs are administered repeatedly, then treatment continues, but drug resistance develops
Solution Approach 1:
The 1,1-cyclobutanedicarboxylic acid complex acts as a mediator that enables continued treatment by reducing the development of drug resistance. The complex form allows the drug to maintain effectiveness over repeated administrations by altering its interaction with tumor cells.
3Reliability
If carboplatin forms stable complex with DNA, then antitumor effect is enhanced, but toxicity to healthy cells increases
Solution Approach 1:
The 1,1-cyclobutanedicarboxylic acid serves as a protective intermediary that modulates carboplatin's interaction with DNA. It reduces the stable complex formation with healthy cell DNA (lowering toxicity) while maintaining or enhancing the antitumor effect against resistant cancer cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The carboplatin complex, or carboplatin 4.0, exhibits improved stability, reduced toxicity, and broader clinical indications, including antitumor, antibacterial, and antiviral applications, with enhanced bioavailability and faster drug clearance.
Implementation Method 1
1,1-cyclobutanedicarboxylic acid molecules are introduced into a carboplatin molecule through bonding of hydrogen bonds
Implementation Method 2
enhancing water solubility, stability, and reducing toxicity by blocking platinum's DNA binding, thereby forming a stable complex
Data Source
AI summary
Provided are a carboplatin complex and a pharmaceutical preparation thereof. The carboplatin complex is a complex formed by combining carboplatin and 1,1-cyclobutanedicarboxylic acid through two hydrogen bonds, each of the two hydrogen bonds is formed between a carbonyl oxygen of a carboplatin molecule and a carboxyl hydrogen of a 1,1-cyclobutanedicarboxylic acid molecule. The present disclosure further provides use of the carboplatin complex in manufacture of an antitumor drug, an antibacterial drug, an antifungal drug, or an antiviral drug, and a quality control method for the carboplatin complex.